Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Xiaofei Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6765-8411; OpenAlex author ID A5100447029. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2021: 2 papers · 2022: 9 papers · 2023: 3 papers · 2024: 2 papers

Papers 16

  1. Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib. Co-author DOI 10.1186/s12943-024-01965-5↗
  2. The Role of Bile Acids in Pancreatic Cancer. Co-author DOI 10.2174/0115680096281168231215060301↗
  3. PLA2G2A+ cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8+ cytotoxic T cells. Co-author DOI 10.1016/j.canlet.2023.216095↗
  4. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216206↗
  5. Cuproptosis-related lncRNAs are correlated with tumour metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients. Co-author DOI 10.1049/syb2.12068↗
  6. Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Co-author DOI 10.1002/cac2.12238↗
  7. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.103897↗
  8. Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer. Co-author DOI 10.1155/2022/5634887↗
  9. HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. First author DOI 10.1186/s12935-022-02807-4↗
  10. Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer. Co-author DOI 10.18632/aging.204031↗
  11. Cuproptosis-related lncRNAs are correlated with metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients Co-author DOI 10.21203/rs.3.rs-1645540/v1↗
  12. A novel angiogenesis-based molecular signature related to prognosis and tumor immune interactions of pancreatic cancer. Co-author DOI 10.3389/fcell.2022.1001606↗
  13. Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. Co-author DOI 10.3389/fcell.2022.942225↗
  14. A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer. Co-author DOI 10.3390/ijms24010156↗
  15. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Co-author DOI 10.1038/s41421-021-00271-4↗
  16. CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling pathway. First author DOI 10.7150/jca.54482↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiujie Cui · 15 shared papers, 2021–2024 · strength 2.17
  2. Tiebo Mao · 15 shared papers, 2021–2024 · strength 2.13
  3. Weiyu Ge · 12 shared papers, 2022–2024 · strength 1.74
  4. Shengbai Xue · 10 shared papers, 2022–2024 · strength 1.52
  5. Liwei Wang · 8 shared papers, 2021–2023 · strength 1.08
  6. Jiayu Yao · 7 shared papers, 2021–2022 · strength 0.85
  7. Shumin Li · 4 shared papers, 2022–2023 · strength 0.55
  8. Liwei Wang · 3 shared papers, 2022–2024 · strength 0.50
  9. Yanling Wang · 3 shared papers, 2022–2024 · strength 0.50
  10. Liwei Wang · 3 shared papers, 2022 · strength 0.44
  11. Yanling Wang · 3 shared papers, 2022–2023 · strength 0.41
  12. Ming Quan · 2 shared papers, 2023–2024 · strength 0.34
  13. Feng Jiao · 3 shared papers, 2021–2022 · strength 0.32
  14. Jiong Hu · 3 shared papers, 2021–2022 · strength 0.32
  15. Yongwei Sun · 3 shared papers, 2021–2022 · strength 0.32
  16. Deliang Fu · 3 shared papers, 2021–2022 · strength 0.32
  17. Xiao Zhang · 2 shared papers, 2021–2022 · strength 0.29
  18. Yingbin Liu · 2 shared papers, 2022 · strength 0.22
  19. Yuexiang Wang · 2 shared papers, 2022 · strength 0.22
  20. Yu Wang · 2 shared papers, 2021–2022 · strength 0.21
  21. Lei Wang · 1 shared paper, 2024 · strength 0.18
  22. Haiyan Yang · 1 shared paper, 2024 · strength 0.18
  23. Yanling Wang · 1 shared paper, 2022 · strength 0.17
  24. Yu Wang · 1 shared paper, 2022 · strength 0.11
  25. Qiang Liu · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.